Scott M. Coiante - 28 Jul 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
SVP, Chief Financial Officer
Signature
/s/ Scott M. Coiante
Issuer symbol
APRE
Transactions as of
28 Jul 2022
Transactions value $
$0
Form type
4
Filing time
01 Aug 2022, 17:00:42 UTC
Previous filing
07 Jun 2022
Next filing
25 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $0 +60.8K +72.15% $0.00 145K 28 Jul 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Option (right to Buy) Award $0 +89.2K $0.00 89.2K 28 Jul 2022 Common Stock 89.2K $1.09 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 20,266 shares on July 28, 2023, (ii) 20,267 shares on July 28, 2024 and (iii) 20,267 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2 Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.